Outlook Therapeutics, Inc. 8-K

What Happened Outlook Therapeutics, Inc. announced that Dr. Julia Haller resigned from the Company's Board of Directors, effective March 11, 2026. The Board resolved to reduce its size to nine directors immediately upon her resignation. Dr. Haller was a Class II director and served on the Nominating and Corporate Governance Committee. The company said the resignation was not due to any dispute or disagreement with management or the Board.

Key Details

• Dr. Julia Haller submitted a resignation dated March 6, 2026; resignation effective March 11, 2026.
• The Board will decrease its total number of directors to nine immediately upon the effective date.
• Dr. Haller was a Class II director and a member of the Nominating and Corporate Governance Committee.
• The resignation letter is included as Exhibit 99.1 to the Form 8-K filed March 11, 2026.

Why It Matters A board member departure is a governance change investors should note. The filing indicates an orderly transition (no dispute), and the company reduced board size rather than immediately naming a replacement. There was no disclosure of financial impact or other operational changes in the 8-K; investors may watch for future filings if the Board announces a new director or committee reassignments.